Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present invention relates to recombinant Corynebacterium having 1,3-PDO productivity and reduced 3-HP productivity, and a method for producing 1,3-PDO by using same. When a Corynebacterium glutamicum variant according to the present invention is used, the productivity of 3-HP, which is a by-product, is inhibited by using low-cost glycerol as a carbon source, and thus 1,3-PDO can be produced with high efficiency.

Abstract: The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.

Abstract: The present invention relates to a method of purifying native ubiquitin without acid or heat treatment. The method presented here is designed to overcome limitations of acid or heat based ubiquitin purification in two different points of view. First, it decreases a chance of mixing other proteins resistant to acids or heat. Second, it includes no harsh condition, which might denature the ubiquitin. As a result, the purification of native ubiquitin becomes possible. The ubiquitin obtained herein is expected to be used for various purposes in technical fields.

Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.

Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.

Abstract: The present disclosure relates to the production of steviol glycosides rebaudioside J and rebaudioside N through the use of rebaudioside A as a substrate and a biosynthetic pathway involving various 1,2 RhaT-rhamnosyltransferases.

Abstract: The present invention relates to a variant pullulanase, wherein the pullulanase comprises at least the following combination of substitutions: N368G+N393A+Q431E+L432F+A492A,S+N610R+G624S+T631S+S632C, and optionally further comprises N222P+Q252A+Q256R; wherein the variant has pullulanase activity, and wherein the variants have at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 3. Further aspect the present invention relates to a process for liquefying starch-containing material at a temperature above the initial gelatinization temperature using an alpha-amylase and a thermo-stable pullulanase of the invention.

Abstract: An automatic dishwashing cleaning composition having a new protease.

Abstract: An ultrasonic-assisted method for preparing phosphatidylserine, comprising the following steps: adding 100-130 parts of phospholipid into a mixture of 150-200 parts of L-serine, 10-20 parts of anhydrous calcium chloride and 400-500 parts of pure water, adding 20-25 parts of phospholipase D for enzymatic hydrolysis reaction, and applying ultrasound in the enzymatic hydrolysis reaction for treatment. The present invention uses an ultrasonic treatment technology to assist phospholipase D to act on phosphatidylcholine and serine to undergo an enzymatic hydrolysis reaction to prepare phosphatidylserine, and at the same time, the ultrasonic frequency, ultrasonic intensity, ultrasonic power, ultrasonic time, ultrasonic temperature, enzyme activity and other parameters are controlled synergistically, so that the enzymatic hydrolysis conversion rate is 98% or higher.

Abstract: The present invention provides a method for producing L-methionine by fermentation using a bacterium belonging to the genus Pantoea which has been modified to overexpress the rarD gene or a mutant gene thereof.

Abstract: The present invention relates to cellobiohydrolase variants and carbohydrate binding module variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (?)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

Abstract: The present invention relates to genetically engineered organisms, especially microorganisms such as bacteria and yeasts, for the production of added value bio-products such as specialty saccharide, activated saccharide, nucleoside, glycoside, glycolipid or glycoprotein. More specifically, the present invention relates to host cells that are metabolically engineered so that they can produce said valuable specialty products in large quantities and at a high rate by bypassing classical technical problems that occur in biocatalytical or fermentative production processes.

Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.

Abstract: The present invention provides a phospholipase D having an amino acid sequence as shown in SEQ ID NO. 1, and further provides a gene sequence encoding phospholipase D, which has a nucleotide sequence as shown in SEQ ID NO. 2. The present invention also provides a method for improving the expression level of phospholipase D by systematically engineering the expression elements. The method comprises screening and replacement of signal peptides, ribosome binding sites and promoters. The constructed recombinant plasmid is transformed into a host cell, and the recombinant strain is capable of successfully expressing phospholipase D. The phospholipase D of the present invention has a good phosphatidyl transferring ability, and can be used for synthesizing the product phosphatidylserine with lecithin and L-serine as substrates. The recombinant strain has good stability of enzyme activity and short fermentation period, which lays the foundation for large-scale industrial production.

Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.

Abstract: The present invention aims to provide a modified Cas9 protein with relaxed restriction on target sequence while maintaining binding ability to guide RNA, and use thereof. A protein containing the amino acid sequence of SEQ ID NO: 1 in which the 1335-position arginine is mutated into alanine (R1335A), isoleucine (R1335I), methionine (R1335M), threonine (R1335T) or valine (R1335V), the 1111-position leucine is mutated into arginine (L1111R), the 1135-position aspartic acid is mutated into valine (D1135V), the 1218-position glycine is mutated into arginine (G1218R), the 1219-position glutamic acid is mutated into phenylalanine (E1219F), the 1322-position alanine is mutated into arginine (A1322R), and the 1337-position threonine is mutated into arginine (T1337R), and the like.

Abstract: The present invention relates to a method for preparing an adipate ester or thioester. The invention further relates to a method for preparing adipic acid from said ester or thioester. Further the invention provides a number of methods for preparing an intermediate for said ester or thioester. Further the invention relates to a method for preparing 6-amino caproic acid (6-ACA), a method for preparing 5-formyl valeric acid (5-FVA), and a method for preparing caprolactam. Further, the invention relates to a host cell for use in a method according to the invention.